Rezolute (RZLT) Long-Term Debt Repayments (2012 - 2014)

Rezolute (RZLT) reported Long-Term Debt Repayments of $67500.0 for Q1 2014, up 90.14% sequentially from $35500.0 in Q1 2012.

Rezolute (RZLT) Long-Term Debt Repayments (2012 - 2014) Analysis & Trends

Rezolute (RZLT) has 2 years of Long-Term Debt Repayments data on file, last reported at $67500.0 in Q1 2014.

For the quarter ending Q1 2014, Long-Term Debt Repayments changed N/A year-over-year to $67500.0; the trailing twelve-month figure through Jun 2014 stood at $67500.0 (changed N/A YoY), and the FY2014 full-year result was $67500.0, changed N/A from the prior year.
Long-Term Debt Repayments rose to $67500.0 in Q1 2014, from $35500.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $67500.0 in Q1 2014 to a low of $35500.0 in Q1 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	7.64 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Rezolute	518.12 Mn	518.12 Mn	-	-

Download Data